Ductal carcinoma in situ

State of the science and roadmap to advance the field

Henry M. Kuerer, Constance T. Albarracin, Wei T. Yang, Robert Cardiff, Abenaa M. Brewster, W. Fraser Symmans, Nola M. Hylton, Lavinia P. Middleton, Savitri Krishnamurthy, George H. Perkins, Gildy Babiera, Mary E. Edgerton, Brian J. Czerniecki, Banu K. Arun, Gabriel N. Hortobagyi

Research output: Contribution to journalReview article

101 Citations (Scopus)

Abstract

Purpose: Ductal carcinoma in situ (DCIS) is the fourth leading cancer for women in the United States. Understanding of the biology and clinical behavior of DCIS is imperfect. This article highlights the current knowledge base and the scientific roadmap needed to advance the field. Methods: This article is based on work done by and consultations obtained from leading experts in the field over a 6-month period that culminated in a full-day symposium designed to systematically review the most pertinent MEDLINE published reports and develop a roadmap to elucidate the molecular steps of carcinogenesis, reduce the extent or prevent the need for therapies, eliminate recurrences, and reduce morbidity. Results: Expression profiling of pure DCIS will help elucidate the molecular characteristics that distinguish high-risk lesions from clinically irrelevant lesions. The development of new methods of extracting RNA from processed tissues may provide opportunities for research. Mammography often underestimates the pathologic extent of DCIS; other imaging methods need to be investigated for detection and monitoring of disease stability or progression. Novel biologic agents are being delivered in neoadjuvant clinical trials, and alternative methods for breast irradiation are being studied. Future trials of treatment versus no treatment for biologically selected cases of DCIS should be developed. Conclusion: There is a critical need for a concerted international effort among patients with DCIS, clinicians, and basic scientists to conduct the research necessary to improve fundamental understanding of the biology and clinical behavior of DCIS and prevent development of invasive breast cancer.

Original languageEnglish (US)
Pages (from-to)279-288
Number of pages10
JournalJournal of Clinical Oncology
Volume27
Issue number2
DOIs
StatePublished - Jan 10 2009
Externally publishedYes

Fingerprint

Carcinoma, Intraductal, Noninfiltrating
Knowledge Bases
Biological Factors
Mammography
Research
MEDLINE
Carcinogenesis
Breast
Therapeutics
Referral and Consultation
Clinical Trials
RNA
Breast Neoplasms
Morbidity
Recurrence

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Kuerer, H. M., Albarracin, C. T., Yang, W. T., Cardiff, R., Brewster, A. M., Symmans, W. F., ... Hortobagyi, G. N. (2009). Ductal carcinoma in situ: State of the science and roadmap to advance the field. Journal of Clinical Oncology, 27(2), 279-288. https://doi.org/10.1200/JCO.2008.18.3103

Ductal carcinoma in situ : State of the science and roadmap to advance the field. / Kuerer, Henry M.; Albarracin, Constance T.; Yang, Wei T.; Cardiff, Robert; Brewster, Abenaa M.; Symmans, W. Fraser; Hylton, Nola M.; Middleton, Lavinia P.; Krishnamurthy, Savitri; Perkins, George H.; Babiera, Gildy; Edgerton, Mary E.; Czerniecki, Brian J.; Arun, Banu K.; Hortobagyi, Gabriel N.

In: Journal of Clinical Oncology, Vol. 27, No. 2, 10.01.2009, p. 279-288.

Research output: Contribution to journalReview article

Kuerer, HM, Albarracin, CT, Yang, WT, Cardiff, R, Brewster, AM, Symmans, WF, Hylton, NM, Middleton, LP, Krishnamurthy, S, Perkins, GH, Babiera, G, Edgerton, ME, Czerniecki, BJ, Arun, BK & Hortobagyi, GN 2009, 'Ductal carcinoma in situ: State of the science and roadmap to advance the field', Journal of Clinical Oncology, vol. 27, no. 2, pp. 279-288. https://doi.org/10.1200/JCO.2008.18.3103
Kuerer, Henry M. ; Albarracin, Constance T. ; Yang, Wei T. ; Cardiff, Robert ; Brewster, Abenaa M. ; Symmans, W. Fraser ; Hylton, Nola M. ; Middleton, Lavinia P. ; Krishnamurthy, Savitri ; Perkins, George H. ; Babiera, Gildy ; Edgerton, Mary E. ; Czerniecki, Brian J. ; Arun, Banu K. ; Hortobagyi, Gabriel N. / Ductal carcinoma in situ : State of the science and roadmap to advance the field. In: Journal of Clinical Oncology. 2009 ; Vol. 27, No. 2. pp. 279-288.
@article{e8e09f82ad8149b59945bcc16443a32a,
title = "Ductal carcinoma in situ: State of the science and roadmap to advance the field",
abstract = "Purpose: Ductal carcinoma in situ (DCIS) is the fourth leading cancer for women in the United States. Understanding of the biology and clinical behavior of DCIS is imperfect. This article highlights the current knowledge base and the scientific roadmap needed to advance the field. Methods: This article is based on work done by and consultations obtained from leading experts in the field over a 6-month period that culminated in a full-day symposium designed to systematically review the most pertinent MEDLINE published reports and develop a roadmap to elucidate the molecular steps of carcinogenesis, reduce the extent or prevent the need for therapies, eliminate recurrences, and reduce morbidity. Results: Expression profiling of pure DCIS will help elucidate the molecular characteristics that distinguish high-risk lesions from clinically irrelevant lesions. The development of new methods of extracting RNA from processed tissues may provide opportunities for research. Mammography often underestimates the pathologic extent of DCIS; other imaging methods need to be investigated for detection and monitoring of disease stability or progression. Novel biologic agents are being delivered in neoadjuvant clinical trials, and alternative methods for breast irradiation are being studied. Future trials of treatment versus no treatment for biologically selected cases of DCIS should be developed. Conclusion: There is a critical need for a concerted international effort among patients with DCIS, clinicians, and basic scientists to conduct the research necessary to improve fundamental understanding of the biology and clinical behavior of DCIS and prevent development of invasive breast cancer.",
author = "Kuerer, {Henry M.} and Albarracin, {Constance T.} and Yang, {Wei T.} and Robert Cardiff and Brewster, {Abenaa M.} and Symmans, {W. Fraser} and Hylton, {Nola M.} and Middleton, {Lavinia P.} and Savitri Krishnamurthy and Perkins, {George H.} and Gildy Babiera and Edgerton, {Mary E.} and Czerniecki, {Brian J.} and Arun, {Banu K.} and Hortobagyi, {Gabriel N.}",
year = "2009",
month = "1",
day = "10",
doi = "10.1200/JCO.2008.18.3103",
language = "English (US)",
volume = "27",
pages = "279--288",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "2",

}

TY - JOUR

T1 - Ductal carcinoma in situ

T2 - State of the science and roadmap to advance the field

AU - Kuerer, Henry M.

AU - Albarracin, Constance T.

AU - Yang, Wei T.

AU - Cardiff, Robert

AU - Brewster, Abenaa M.

AU - Symmans, W. Fraser

AU - Hylton, Nola M.

AU - Middleton, Lavinia P.

AU - Krishnamurthy, Savitri

AU - Perkins, George H.

AU - Babiera, Gildy

AU - Edgerton, Mary E.

AU - Czerniecki, Brian J.

AU - Arun, Banu K.

AU - Hortobagyi, Gabriel N.

PY - 2009/1/10

Y1 - 2009/1/10

N2 - Purpose: Ductal carcinoma in situ (DCIS) is the fourth leading cancer for women in the United States. Understanding of the biology and clinical behavior of DCIS is imperfect. This article highlights the current knowledge base and the scientific roadmap needed to advance the field. Methods: This article is based on work done by and consultations obtained from leading experts in the field over a 6-month period that culminated in a full-day symposium designed to systematically review the most pertinent MEDLINE published reports and develop a roadmap to elucidate the molecular steps of carcinogenesis, reduce the extent or prevent the need for therapies, eliminate recurrences, and reduce morbidity. Results: Expression profiling of pure DCIS will help elucidate the molecular characteristics that distinguish high-risk lesions from clinically irrelevant lesions. The development of new methods of extracting RNA from processed tissues may provide opportunities for research. Mammography often underestimates the pathologic extent of DCIS; other imaging methods need to be investigated for detection and monitoring of disease stability or progression. Novel biologic agents are being delivered in neoadjuvant clinical trials, and alternative methods for breast irradiation are being studied. Future trials of treatment versus no treatment for biologically selected cases of DCIS should be developed. Conclusion: There is a critical need for a concerted international effort among patients with DCIS, clinicians, and basic scientists to conduct the research necessary to improve fundamental understanding of the biology and clinical behavior of DCIS and prevent development of invasive breast cancer.

AB - Purpose: Ductal carcinoma in situ (DCIS) is the fourth leading cancer for women in the United States. Understanding of the biology and clinical behavior of DCIS is imperfect. This article highlights the current knowledge base and the scientific roadmap needed to advance the field. Methods: This article is based on work done by and consultations obtained from leading experts in the field over a 6-month period that culminated in a full-day symposium designed to systematically review the most pertinent MEDLINE published reports and develop a roadmap to elucidate the molecular steps of carcinogenesis, reduce the extent or prevent the need for therapies, eliminate recurrences, and reduce morbidity. Results: Expression profiling of pure DCIS will help elucidate the molecular characteristics that distinguish high-risk lesions from clinically irrelevant lesions. The development of new methods of extracting RNA from processed tissues may provide opportunities for research. Mammography often underestimates the pathologic extent of DCIS; other imaging methods need to be investigated for detection and monitoring of disease stability or progression. Novel biologic agents are being delivered in neoadjuvant clinical trials, and alternative methods for breast irradiation are being studied. Future trials of treatment versus no treatment for biologically selected cases of DCIS should be developed. Conclusion: There is a critical need for a concerted international effort among patients with DCIS, clinicians, and basic scientists to conduct the research necessary to improve fundamental understanding of the biology and clinical behavior of DCIS and prevent development of invasive breast cancer.

UR - http://www.scopus.com/inward/record.url?scp=58249090928&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58249090928&partnerID=8YFLogxK

U2 - 10.1200/JCO.2008.18.3103

DO - 10.1200/JCO.2008.18.3103

M3 - Review article

VL - 27

SP - 279

EP - 288

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 2

ER -